23948sdkhjf
  • {{ window.visitor.corporateClient.name }}
    Företagslösning
    {{ window.visitor.ipAccess.corporateClient.name }}
    {{ window.visitor.corporateClient.name }}

  • Välkommen till vår företagslösning

    Här kan du administrera användarna i din företagslösning.

  • Welcome to our Corporate client solution

    Your IP is registered with the company mentioned above and provides access to Life Science Sweden.

  • Click here to go to sign-up
Logga in eller skapa en prenumeration för att spara artiklar
Få tillgång till allt innehåll på Life Science Sweden
Ingen bindningstid eller kortinformation krävs
Prova Life Science Sweden nu
Gäller endast personlig prenumeration.
Kontakta oss för en företagslösning.
Annons
Annons
News in English

Samuel Lagercrantz: ”Obesity, blockbusters and Swedish biotech”

The development of technologies to bypass the blood-brain barrier is particularly exciting right now, as it holds the potential to unlock new treatments for a range of neurological diseases, according to Samuel Lagercrantz.
Annons

At the time of writing, it is still early in 2026. This year’s major pharmaceutical blockbusters are expected to be two obesity drugs. As before, Novo Nordisk and Eli Lilly are leading development in the field.

According to analysis firm Evaluate, Novo’s dual-acting injectable CagriSema and Lilly’s oral drug orforglipron are projected to generate revenues of USD 17.2 billion and USD 11.8 billion respectively through 2032. Both drugs could be approved in the US this year and likely in the EU in 2027.

Annons Annons
BREAKING
{{ article.headline }}
0.193|